[Page Banner Image]

The following is a review of diagnostic product developments worldwide

The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.

The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

[HRule Image]

Product developments in May 2005

Dear Reader, Thank you for your continued support and encouragement. Please note: As is our custom, we are taking a short summer break and will be back in September with our monthly updates. Take care, enjoy the summer. See you in September.

Accumetrics' VerifyNow Aspirin Test has been granted a CLIA waiver by the FDA. The test provides a rapid result that identifies a patient's responsiveness to aspirin therapy.

BioArray Solutions, Ltd. is developing the HEA (Human Erythrocyte Antigen) BeadChip Test that includes 18 human erythrocyte antigens other than those in ABO and Rh antigen groups and including those in the Duffy, Kell, Kidd, Lutheran, MNS, Dombrock and a mutation associated with sickle cell disease. The assay format employs a single tube multiplex PCR amplification.

bioMérieux SA has acquired an option to license Applied NeuroSolutions' Alzheimer's disease tests. bioMérieux will be financially responsible for securing regulatory approvals to develop and sell diagnostic tests based on Applied Neurosolutions' research on a blood test.

Correlogic Systems, Inc. entered into a research collaboration with the Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine whereby USU's Center for Prostate Disease Research and the Foundation will collaborate with Correlogic on a study on the use of Correlogic's protein pattern recognition approach and technology in prostate cancer. The goal is to develop a more effective blood test for the detection of prostate cancer.

DexCom Inc. announced that its PMA for the DexCom Short-Term Continuous Glucose Sensor submitted in March 2005 has been accepted and granted expedited review status.

Glycominds was awarded the CE MARK for its IBDX products, a series of blood tests for Crohn's Disease, enabling differential diagnosis between Crohn's disease, ulcerative colitis and irritable bowel syndrome.

Inverness Medical Innovations acquired Abbott Diagnostics' Determine/DainaScreen assets which provide rapid qualitative results for infectious diseases, including hepatitis, HIV and syphilis. Under the terms of the agreement Inverness will acquire the Determine/DainaScreen rapid diagnostics menu for $56.5 million. The assets include manufacturing equipment, and certain transferred and licensed intellectual property related to the products. Abbott will continue to distribute the Determine products, which are marketed outside of the United States, for up to 32 months and will receive a sales commission on net sales. Under a long term supply arrangement Inverness will sell product to Abbott which will allow Abbott to continue to distribute the Determine HIV 1/2 rapid test at no profit to Abbott through the Abbott Access to HIV Care program in 69 developing countries.

Inverness Medical Innovations' subsidiary, Wampole Laboratories, LLC, signed an agreement with ThyroTec Inc. to serve as the exclusive North American distributor of ThyroTest, a rapid immunoassay screen for TSH in whole blood. ThyroTest is the first rapid format TSH test to receive FDA clearance and CLIA waiver.

SomaLogic, Inc., entered a technology development agreement with Quest Diagnostics Incorporated to develop new diagnostic tests based on SomaLogic's aptamer array platform in the areas of oncology, as well as cardiovascular, autoimmune, and infectious diseases. In addition, Quest Diagnostics has made a $15 million equity investment in SomaLogic.

Tessera Inc. in collaboration with the Brady Urological Research Institute at Johns Hopkins University is developing blood tests for prostate and colon cancer. The company is begining with EPCA (Early Prostate Cancer Antigen).

[HRule Image]

* Product developments - April 2005
* Product developments - March 2005
* Product developments - February 2005
* Product developments - January 2005
* Product developments - December 2004
* Product developments - November 2004
* Product developments - October 2004
* Product developments - September 2004
* Product developments - May 2004
* Product developments - April 2004
* Product developments - March 2004
* Product developments - February 2004
* Product developments - January 2004
* Product developments - December 2003
* Product developments - November 2003
* Product developments - October 2003
* Product developments - September 2003
* Product developments - Summer 2003
* Product developments - May 2003
* Product developments - April 2003
* Product developments - March 2003
* Product developments - April 04003
* Product developments - January 2003
* Product developments - December 2002
* Product developments - November 2002
* Product developments - October 2002
* Product developments - September 2002
* Product developments - Summer 2002
* Product developments - June 2002
* Product developments - May 2002
* Product developments - April 2002
* Product developments - March 2002
* Product developments - April 04002
* Product developments - January 2002
* Product developments - December 2001
* Product developments - November 2001
* Product developments - October 2001
* Product developments - September 2001
* Product developments - Summer 2001
* Product developments - May 2001
* Product developments - April 2001
* Product developments - March 2001
* Product developments - April 04001
* Product developments - January 2001
* Product developments - December 2000
* Product developments - November 2000
* Product developments - October 2000
* Product developments - September 2000
* Product developments - July - August 2000
* Product developments - June 2000
* Product developments - May 2000
* Product developments - April 2000
* Product developments - March 2000
* Product developments - Febuary 2000
* Product developments - January 2000
* Product developments - December 1999
* Product developments - November 1999
* Product developments - October 1999
* Product developments - September 1999
* Product developments - August 1999
* Product developments - July 1999
* Product developments - June 1999
* Product developments - May 1999
* Product developments - April 1999
* Product developments - March 1999
* Product developments - Febuary 1999
* Product developments - January 1999
* Product developments - December 1998
* Product developments - November 1998
* Product developments - October 1998
* Product developments - September 1998
* Product developments - August 1998
* Product developments - July 1998
* Product developments - June 1998
* Product developments - May 1998
* Product developments - Avril 1998
* Product developments - March 1998
* Product developments - February 1998
* Product developments - January 1998
* Product developments - July 1997
* Product developments - June 1997
* Product developments - May 1997
* Product developments - April 1997
* Product developments - March 1997
* Product developments - February 1997
* Product developments - January 1997
* Product developments - December 1996
* Product developments - November 1996
* Product developments - October 1996
* Product developments - September 1996
* Product developments - August 1996
* Product developments - July 1996
* Product developments - June 1996

[HRule Image]

Home | Company Profile | Services | Research Reports Available
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links

[HRule Image]
Send mail to stratcom@pagebleu.com with questions or comments about this web site.

Concept and Design Blue Page Productions
Copyright © 1996-2005 STRATCOM

Last modified: June 6, 2005